Karl Nägler
Life Science Investor at Sofinnova Partners
Greater Munich Metropolitan Area
Skills
Education
- FU
- MU
Work Experience
2024
Partner
2024
2020 - 2024
Managing Partner
2020 - 2024
Representing Wellington on the boards of: - Imcheck Therapeutics (www.imchecktherapeutics.com; Marseille) - Minervax (www.minervax.com; Kopenhagen) - SIRS Therapeutics (www.wellington-partners.com/port/sirs/; Munich) - Uromems (www.uromems.com; Grenoble) - Advanced Medical Balloons (www.hyghtec.com; Waghäusel) - Confo Therapeutics (www.confotherapeutics.com; Ghent) - Seamless Therapeutics (https://seamlesstx.com; Dresden)
2011 - 2019
Partner
2011 - 2019
Led Gimv's investments in, and represented Gimv on the boards of: - Precirix (www.precirix.com - Brussels) - Imcheck Therapeutics (www.imchecktherapeutics.com - Marseille) - Breath Therapeutics (Munich; acquired by Zambon) - Topas Therapeutics (www.topas-therapeutics.com - Prosonix (Oxford; acquired by Circassia, CIR:LN) and - Covagen (Zurich; acquired by Johnson & Johnson, JNJ:US); Chairman of the board Also represented Gimv on the board of Actogenix (Gent; acquired by Intrexon, XON:US)
2009 - 2011
General Partner
2009 - 2011
Led Ventech's investments in, and represented Ventech on the boards of: - Prosonix (Oxford; acquired by Circassia, CIR:LN) - Covagen (Zurich; acquired by Johnson & Johnson, JNJ:US) - Funxional Therapeutics (Cambridge; acquired by Boehringer Ingelheim) - Themis (Vienna; acquired by MSD, MRK:NYS) Also represented Ventech on the board of Actogenix (Gent; acquired by Intrexon, XON:US)
2002 - 2009
Principal
2002 - 2009
Led Atlas' financings in, and represented Atlas on the boards of: - Nitec Pharma (Basel; acquired by Horizon Pharma, HZNP:US) - Egalet (Kopenhagen; IPO on Nasdaq, EGLT:US) - U3 Pharma (Munich; acquired by Daiichi Sankyo, DSKYF:US)
2001 - 2002
Postdoctoral Research Scientist
2001 - 2002
1999 - 2001
Research Scientist
1999 - 2001
PhD position: Cellular and Molecular Neurobiology